治疗绝经后骨质疏松症的临床分析

Clinical analysis of the treatment on postmenopausal osteoporosis

目的探讨阿法骨化醇联合阿仑膦酸钠治疗绝经后骨质疏松症的临床疗效。方法选取2010年2月至2012年2月间于万宁市妇幼保健院接受诊断和治疗的绝经后骨质疏松症患者84例,随机分为观察组与对照组,每组42例。对照组给予常规补钙治疗,观察组给予阿法骨化醇联合阿仑膦酸钠治疗。治疗周期6个月,比较两组患者骨密度值及临床疗效情况。结果观察组患者治疗后的骨密度值为(0.94±0.11)g/cm^2,明显高于治疗前的(0.82±0.08)g/cm^2和对照组的骨密度值(0.84±0.08)g/cm^2(t值分别为9.131、8.441,均P<0.05)。观察组治疗的显效率为66.67%,明显高于对照组的28.58%(x^2=9.784,P<0.05);无效率为9.52%,明显低于对照组的35.71%(x^2=8.561,P<0.05)。结论 阿法骨化醇联合阿仑膦酸钠治疗绝经后骨质疏松症临床疗效显著,值得推广应用。

Objective To discuss the clinical effect of alfacalcidol combined with alendronate in treating postmenopausal osteoporosis. Methods Totally 84 cases of postmenopansal osteoporosis in Wanning Maternal and Child Health Hospital were selected from February 2010 to February 2012, and they were randomly divided into observation group and control group with 42 cases in each group. The control group received conventional treatment, while alfacalcidol combined with alendronate was given to the observation group. The bone density and clinical effect or two groups were compared after treatment for 6 months. Results The bone density of the observation group after treatment was（0.94 ± 0. llg/cm2 ） , and it was obviously higher than that before treatment （0.82 ± 0. 08） g/cm2 and that of the control group（0. 84 ± 0.08g/em2 ） （ t value was 9. 131 and 8. 441, respectively, both P 〈 0.05 ）. The effective rate of the observation group was 66.67%, which was obviously higher than that of the control group （28.58%） （X2 = 9. 784, P 〈 0.05 ）. The ineffective rate of the observation group was obviously lower than that of the control group （9.52% vs 35.71% ） （X2 = 8. 561, P 〈 0.05）. Conclusion The treatment on postmenopausal osteoporosis by alfacalcidol combined with alendronate has significant efficacy and deserves promotion.